Cannabis Science Inc (fka CBIS)

[Smokin Moose]

Cannabis and Cancer - list of references Part 2
201. Kogan, N. M. & Mechoulam, R. Cannabinoids in health and disease. Dialogues Clin Neurosci 9, 413-430 (2007).
202. Goanvic, D. L. & Tius, M. A. Oxaza adamantyl cannabinoids. A new class of cannabinoid receptor probes. J Org Chem 71, 7800-7804 (2006).
203. Pacher, P., Batkai, S. & Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58, 389-462 (2006).
204. Karanian, D. A. & Bahr, B. A. Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states. Curr Mol Med 6, 677-684 (2006).
205. Ziring, D. et al. Formation of B and T cell subsets require the cannabinoid receptor CB2. Immunogenetics 58, 714-725 (2006).
206. Ligresti, A. et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318, 1375- 1387 (2006).
207. Sarfaraz, S., Afaq, F., Adhami, V. M., Malik, A. & Mukhtar, H. Cannabinoid receptor agonist induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem (2006).
208. Blazquez, C. et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J (2006).
209. Stokes, A. et al. TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. Cell Signal 18, 1584-1594 (2006).
210. De Lago, E. et al. Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. J Neurochem 99, 677-688 (2006).
211. Xu, X. et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 171, 31-38 (2006).
212. Fernandez-Solari, J., Prestifilippo, J. P., Bornstein, S. R., McCann, S. M. & Rettori, V. Participation of the Endocannabinoid System in the Effect of TNF-{alpha} on Hypothalamic Release of Gonadotropin-Releasing Hormone. Ann N Y Acad Sci S 1088, 238-250 (2006).
213. Mormina, M. E., Thakur, S., Molleman, A., Whelan, C. J. & Baydoun, A. R. Cannabinoid signalling in TNF-alpha induced IL-8 release. Eur J Pharmacol (2006).
214. Raduner, S. et al. Alkylamides from Echinacea Are a New Class of Cannabinomimetics: CANNABINOID TYPE 2 RECEPTOR-DEPENDENT AND - INDEPENDENT IMMUNOMODULATORY EFFECTS. J Biol Chem 281, 14192- 14206 (2006).
215. Alsasua Del Valle, A. Implication of Cannabinoids in Neurological Diseases. Cell Mol Neurobiol (2006).
216. Bifulco, M., Laezza, C., Pisanti, S. & Gazzerro, P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148, 123-135 (2006).
217. Kogan, N. M. et al. A Cannabinoid Quinone Inhibits Angiogenesis by Targeting Vascular Endothelial Cells. Mol Pharmacol (2006).
218. Fogli, S. et al. Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. FEBS Lett 580, 1733-1739 (2006).
219. Bari, M., Battista, N., Fezza, F., Gasperi, V. & Maccarrone, M. New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem 6, 257-268 (2006).
220. Fernandez-Lopez, D. et al. Characterization of the Neuroprotective Effect of the Cannabinoid Agonist WIN-55212 in an In Vitro Model of Hypoxic-Ischemic Brain Damage in Newborn Rats. Pediatr Res (2006).
221. Guzman, M. et al. A pilot clinical study of Delta(9)-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer (2006).
222. Sarnataro, D. et al. The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Human Breast Cancer Cell Proliferation Through A Lipid Rafts Mediated Mechanism. Mol Pharmacol (2006).
223. Strasser, F. et al. Comparison of orally administered cannabis extract and delta-9- tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24, 3394- 3400 (2006).
224. Carracedo, A. et al. Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via Endoplasmic Reticulum Stress-Related Genes. Cancer Res 66, 6748-6755 (2006).
225. Caffarel, M. M., Sarrio, D., Palacios, J., Guzman, M. & Sanchez, C. Delta}9- Tetrahydrocannabinol Inhibits Cell Cycle Progression in Human Breast Cancer Cells through Cdc2 Regulation. Cancer Res 66, 6615-6621 (2006).
226. Guagnini, F. et al. Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut 55, 946-953 (2006).
227. Roberts, J. D., Gennings, C. & Shih, M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 530, 54-58 (2006).
228. Eichele, K., Weinzierl, U., Ramer, R., Brune, K. & Hinz, B. R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells. Pharm Res 23, 90-94 (2006).
229. Rao, G. K. & Kaminski, N. E. Induction of intracellular calcium elevation by Delta9-tetrahydrocannabinol in T cells involves TRPC1 channels. J Leukoc Biol 79, 202-213 (2006).
230. Ben-Shabat, S., Hanus, L. O., Katzavian, G. & Gallily, R. New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. J Med Chem 49, 1113-1117 (2006).
231. Grimaldi, C. et al. Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 312, 363-373 (2006).
232. Vignot, S. et al. [Cannabis and cancer]. Bull Cancer 93, 163-170 (2006).
233. Shmist, Y. A. et al. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Mol Cell Biochem 283, 75-83 (2006).
234. Hamamoto, D. T., Giridharagopalan, S. & Simone, D. A. Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor- evoked hyperalgesia. Eur J Pharmacol S (2006).
235. Pisanti, S. et al. Antiangiogenic activity of the endocannabinoid anandamide: Correlation to its tumor-suppressor efficacy. J Cell Physiol S (2006).
236. Ellert-Miklaszewska, A., Grajkowska, W., Gabrusiewicz, K., Kaminska, B. & Konarska, L. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res S (2006).
237. Huang, H., Nishi, K., Tsai, H. J. & Hammock, B. D. Development of highly sensitive fluorescent assays for fatty acid amide hydrolase. Anal Biochem SO - Anal Biochem. 2006 Dec 20;d (2006).
238. Davis, M., Maida, V., Daeninck, P. & Pergolizzi, J. The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer (2006).
239. Wang, H. et al. Fatty acid amide hydrolase deficiency limits early pregnancy events. J Clin Invest 116, 2122-2131 (2006).
240. Jia, W. et al. Delta}9-Tetrahydrocannabinol-Induced Apoptosis in Jurkat Leukemia T Cells Is Regulated by Translocation of Bad to Mitochondria. Mol Cancer Res 4, 549-562 (2006).
241. Held-Feindt, J., Dorner, L., Sahan, G., Mehdorn, H. M. & Mentlein, R. Cannabinoid receptors in human astroglial tumors. J Neurochem 98, 886-893 (2006).
242. Perez, J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc) 42, 495-503 (2006).
243. Matias, I. et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91, 3171-3180 (2006).
244. Ben Amar, M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 105, 1-25 (2006).
245. Herrera, B. et al. The CB(2) cannabinoid receptor signals apoptosis via ceramide- dependent activation of the mitochondrial intrinsic pathway. Exp Cell Res (2006).
246. Holland, M. L. et al. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem Pharmacol 71, 1146-1154 (2006).
247. Carracedo, A. et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9, 301-312 (2006).
248. Verhoeckx, K. C. et al. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int Immunopharmacol 6, 656-665 (2006).
249. Singh, J. & Budhiraja, S. Therapeutic potential of cannabinoid receptor ligands: current status. Methods Find Exp Clin Pharmacol 28, 177-183 (2006).
250. Russo, E. & Guy, G. W. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66, 234-246 (2006).
251. Vidinsky, B., Gal, P. & Mojzis, J. [Different views on the association between cannabinoids and cancer]. Cas Lek Cesk 145, 453-7; discussion 458-9 (2006).
252. Massi, P., Vaccani, A. & Parolaro, D. Cannabinoids, immune system and cytokine network. Curr Pharm Des 12, 3135-3146 (2006).
253. Huskey, A. Cannabinoids in cancer pain management. J Pain Palliat Care Pharmacother 20, 43-46 (2006).
254. Melamede, R. J. Endocannabinoids: Multi-scaled, Global Homeostatic Regulators of Cells and Society. Interjournal Complex Systems 1669 (2006).
255. Sancho, R. et al. Mechanisms of HIV-1 inhibition by the lipid mediator N- arachidonoyldopamine. J Immunol 175, 3990-3999 (2005).
256. Melamede, R. Cannabis and tobacco smoke are not equally carcinogenic. Harm Reduct J 2, 21 (2005).
257. Sun, Y. X. et al. Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim Biophys Acta 1736, 211-220 (2005).
258. Kogan, N. M. Cannabinoids and cancer. Mini Rev Med Chem 5, 941-952 (2005).
259. Sarnataro, D. et al. Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS Lett 579, 6343-6349 (2005).
260. Klein, T. W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5, 400-411 (2005).
261. McKallip, R. J., Nagarkatti, M. & Nagarkatti, P. S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 174, 3281-3289 (2005).
262. Tashkin, D. P. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis 63, 93-100 (2005).
263. Bari, M., Paradisi, A., Pasquariello, N. & Maccarrone, M. Cholesterol-dependent modulation of type 1 cannabinoid receptors in nerve cells. J Neurosci Res 81, 275- 283 (2005).
264. Nithipatikom, K. et al. A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. Biochem Biophys Res Commun 332, 1028-1033 (2005).
265. Watanabe, K. et al. Marijuana extracts possess the effects like the endocrine disrupting chemicals. Toxicology 206, 471-478 (2005).
266. Sheng, W. S. et al. Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49, 211-219 (2005).
267. Ellert-Miklaszewska, A., Kaminska, B. & Konarska, L. Cannabinoids down- regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal 17, 25-37 (2005).
268. Chung, K. F. Drugs to suppress cough. Expert Opin Investig Drugs 14, 19-27 (2005).
269. Hall, W., Christie, M. & Currow, D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 6, 35-42 (2005).
270. Ramirez, B. G., Blazquez, C., Gomez del Pulgar, T., Guzman, M. & de Ceballos, M. L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 25, 1904-1913 (2005).
271. Powles, T. et al. Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 105, 1214-1221 (2005).
272. Radbruch, L. & Elsner, F. Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs 10, 151-171 (2005).
273. Sharma, R., Tobin, P. & Clarke, S. J. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 6, 93-102 (2005).
274. Roila, F. et al. Antiemetics in children receiving chemotherapy. Support Care Cancer 13, 129-131 (2005).
275. Kishimoto, S. et al. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J Biochem (Tokyo) 137, 217-223 (2005).
276. Flygare, J., Gustafsson, K., Kimby, E., Christensson, B. & Sander, B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett 579, 6885-6889 (2005).
277. Lee, S. Y., Oh, S. M., Lee, S. K. & Chung, K. H. Antiestrogenic effects of marijuana smoke condensate and cannabinoid compounds. Arch Pharm Res 28, 1365-1375 (2005).
278. Patsos, H. A., Hicks, D. J., Greenhough, A., Williams, A. C. & Paraskeva, C. Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem Soc Trans 33, 712-714 (2005).
279. Ortega-Gutierrez, S. et al. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J 19, 1338-1340 (2005).
280. Lombard, C., Nagarkatti, M. & Nagarkatti, P. S. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk Res 29, 915-922 (2005).
281. McAllister, S. D. et al. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol 74, 31-40 (2005).
282. Myrianthefs, P. M. & Batistaki, C. Cancer cachexia and immunomodulation. J BUON 10, 181-188 (2005).
283. Bari, M., Battista, N., Fezza, F., Finazzi-Agro, A. & Maccarrone, M. Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. J Biol Chem 280, 12212-12220 (2005).
284. Fride, E., Bregman, T. & Kirkham, T. C. Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. Exp Biol Med (Maywood) 230, 225-234 (2005).
285. Vaccani, A., Massi, P., Colombo, A., Rubino, T. & Parolaro, D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144, 1032-1036 (2005).
286. Guzman, M. Effects on cell viability. Handb Exp Pharmacol 627-642 (2005). 287. Izzo, A. A. & Coutts, A. A. Cannabinoids and the digestive tract. Handb Exp
Pharmacol 573-598 (2005). 288. Burstein, S. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies,
and clinical trials. AAPS J 7, E143-8 (2005). 289. Carlini, E. A. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol
(Delta 9-THC) on humans. Toxicon 44, 461-467 (2004).
290. Medveczky, M. M., Sherwood, T. A., Klein, T. W., Friedman, H. & Medveczky, P. G. Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro. BMC Med 2, 34 (2004).
291. Contassot, E. et al. Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. J Neuropathol Exp Neurol 63, 956-963 (2004).
292. Juttler, E. et al. The cannabinoid dexanabinol is an inhibitor of the nuclear factor- kappa B (NF-kappa B). Neuropharmacology 47, 580-592 (2004).
293. Velasco, G., Galve-Roperh, I., Sanchez, C., Blazquez, C. & Guzman, M. Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacology 47, 315-323 (2004).
294. Inui, A. [Pathogenesis and treatment of cancer anorexia-cachexia, with special emphasis on aged patients]. Nippon Ronen Igakkai Zasshi 41, 460-467 (2004).
295. Bifulco, M. et al. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18, 1606-1608 (2004).
296. Hinz, B., Ramer, R., Eichele, K., Weinzierl, U. & Brune, K. R(+)-methanandamide- induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. Biochem Biophys Res Commun 324, 621-626 (2004).
297. Rukwied, R., Gauter, B., Schley, M. & Konrad, C. [Cannabinoids-signal transduction and mode of action.]. Schmerz (2004).
298. Carter, G. T. & Ugalde, V. Medical marijuana: emerging applications for the management of neurologic disorders. Phys Med Rehabil Clin N Am 15, 943-54, ix (2004).
299. Fowler, C. J., Tiger, G., Ligresti, A., Lopez-Rodriguez, M. L. & Di Marzo, V. Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a difficult issue to handle. Eur J Pharmacol 492, 1-11 (2004).
300. Carter, G. T., Weydt, P., Kyashna-Tocha, M. & Abrams, D. I. Medicinal cannabis: rational guidelines for dosing. IDrugs 7, 464-470 (2004).
301. Matias, I. et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther 309, 745-757 (2004).
302. Duran, M., Laporte, J. R. & Capella, D. [News about therapeutic use of Cannabis and endocannabinoid system]. Med Clin (Barc) 122, 390-398 (2004).
303. Hart, S., Fischer, O. M. & Ullrich, A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res 64, 1943-1950 (2004).
304. Massi, P. et al. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 308, 838-845 (2004).
305. Carracedo, A. et al. Ceramide sensitizes astrocytes to oxidative stress: protective role of cannabinoids. Biochem J 380, 435-440 (2004).
306. Kraft, B. & Kress, H. G. [Cannabinoids and the immune system. Of men, mice and cells]. Schmerz 18, 203-210 (2004).
307. Nauck, F. & Klaschik, E. Cannabinoids in the treatment of the cachexia-anorexia syndrome in palliative care patients. Schmerz 18, 197-202 (2004).
308. Martin, B. R. & Wiley, J. L. Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain. J Support Oncol 2, 305-14; discussion 314-6 (2004).
309. Kogan, N. M. et al. Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J Med Chem 47, 3800-3806 (2004).
310. Derkinderen, P., Valjent, E., Darcel, F., Damier, P. & Girault, J. A. [Cannabis and cannabinoid receptors: from pathophysiology to therapeutic options]. Rev Neurol (Paris) 160, 639-649 (2004).
311. Rubovitch, V., Gafni, M. & Sarne, Y. The involvement of VEGF receptors and MAPK in the cannabinoid potentiation of Ca2+ flux into N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 120, 138-144 (2004).
312. Desreumaux, P., Thuru, X. & Philippe, D. [Control of secretory diarrhea and colorectal cancer growth by cannabinoids in the gut]. Gastroenterol Clin Biol 28, 97 (2004).
313. Leggett, J. D. et al. Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 141, 253-262 (2004).
314. Sancho, R. et al. Immunosuppressive activity of endovanilloids: N-arachidonoyl- dopamine inhibits activation of the NF-kappa B, NFAT, and activator protein 1 signaling pathways. J Immunol 172, 2341-2351 (2004).
315. Cabral, G. A. & Marciano-Cabral, F. Cannabinoid-mediated exacerbation of brain infection by opportunistic amebae. J Neuroimmunol 147, 127-130 (2004).
316. Fowler, C. J. Possible involvement of the endocannabinoid system in the actions of three clinically used drugs. Trends Pharmacol Sci 25, 59-61 (2004).
317. Liang, Y. C., Huang, C. C. & Hsu, K. S. Therapeutic potential of cannabinoids in trigeminal neuralgia. Curr Drug Targets CNS Neurol Disord 3, 507-514 (2004).
318. Coutts, A. A. & Izzo, A. A. The gastrointestinal pharmacology of cannabinoids: an update. Curr Opin Pharmacol 4, 572-579 (2004).
319. Blazquez, C. et al. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 64, 5617-5623 (2004).
320. Joseph, J., Niggemann, B., Zaenker, K. S. & Entschladen, F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 53, 723-728 (2004).
321. Kalant, H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 28, 849-863 (2004).
322. Contassot, E., Tenan, M., Schnuriger, V., Pelte, M. F. & Dietrich, P. Y. Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. Gynecol Oncol 93, 182-188 (2004).
323. Maccarrone, M. et al. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor- dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem 278, 33896-33903 (2003).
324. Vannacci, A., Giannini, L., Masini, E. & Mannaioni, P. F. Cannabinoid-induced activation of ERK and AKT in mast cells may be mediated by intracellular NO production. J Immunol 171, 2767 (2003).
325. Fowler, C. J. et al. Inhibition of C6 glioma cell proliferation by anandamide, 1- arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid. Biochem Pharmacol 66, 757-767 (2003).
326. Sanchez, M. G., Ruiz-Llorente, L., Sanchez, A. M. & Diaz-Laviada, I. Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal 15, 851-859 (2003).
327. Portella, G. et al. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 17, 1771-1773 (2003).
328. Ligresti, A. et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125, 677-687 (2003).
329. Croci, T., Landi, M., Galzin, A. M. & Marini, P. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 140, 115-122 (2003).
330. Klein, T. W. et al. The cannabinoid system and immune modulation. J Leukoc Biol 74, 486-496 (2003).
331. Guzman, M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 3, 745-755 (2003).
332. Gardner, B., Zhu, L. X., Sharma, S., Tashkin, D. P. & Dubinett, S. M. Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB J 17, 2157-2159 (2003).
333. Ramer, R., Weinzierl, U., Schwind, B., Brune, K. & Hinz, B. Ceramide is involved in r(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. Mol Pharmacol 64, 1189-1198 (2003).
334. Wrobleski, S. T. et al. Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. J Med Chem 46, 2110-2116 (2003).
335. Samson, M. T. et al. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 170, 4953-4962 (2003).
336. Kehl, L. J. et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 103, 175-186 (2003).
337. Bifulco, M. & Di Marzo, V. [The endocannabinoid system as a target for the development of new drugs for cancer therapy]. Recenti Prog Med 94, 194-198 (2003).
338. Vandevoorde, S., Lambert, D. M., Smart, D., Jonsson, K. O. & Fowler, C. J. N- Morpholino- and N-diethyl-analogues of palmitoylethanolamide increase the sensitivity of transfected human vanilloid receptors to activation by anandamide without affecting fatty acid amidohydrolase activity. Bioorg Med Chem 11, 817-825 (2003).
339. Upham, B. L. et al. Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line. Int J Cancer 104, 12-18 (2003).
340. Kingsley, P. J. & Marnett, L. J. Analysis of endocannabinoids by Ag+ coordination tandem mass spectrometry. Anal Biochem 314, 8-15 (2003).
341. Blazquez, C. et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17, 529-531 (2003).
342. New toke on treating skin cancer. Lab Anim (NY) 32, 12 (2003).
343. Ware, M. A., Doyle, C. R., Woods, R., Lynch, M. E. & Clark, A. J. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 102, 211-216 (2003).
344. Parker, L. A. et al. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology (Berl) 166, 156-162 (2003).
345. Walsh, D., Nelson, K. A. & Mahmoud, F. A. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11, 137-143 (2003).
346. Bruera, E. & Castro, M. Cannabinoids in supportive care: are they necessary? Support Care Cancer 11, 133-134 (2003).
347. Tarzia, G. et al. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem 46, 2352-2360 (2003).
348. Klegeris, A., Bissonnette, C. J. & McGeer, P. L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 139, 775-786 (2003).
349. Bash, R., Rubovitch, V., Gafni, M. & Sarne, Y. The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation. Neurosignals 12, 39-44 (2003).
350. Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M. & Leon, A. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 41, 161-168 (2003).
351. Ihenetu, K., Molleman, A., Parsons, M. E. & Whelan, C. J. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. Eur J Pharmacol 458, 207-215 (2003).
352. Casanova, M. L. et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111, 43-50 (2003).
353. Zurier, R. B., Rossetti, R. G., Burstein, S. H. & Bidinger, B. Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid. Biochem Pharmacol 65, 649-655 (2003).
354. Sarafian, T. et al. Clarifying Cb2 Receptor-dependent and Independent Effects of Thc on Human Lung Epithelial Cells. Toxicol Appl Pharmacol (2008).
355. Davis, M. I., Ronesi, J. & Lovinger, D. M. A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells. J Biol Chem 278, 48973-48980 (2003).
356. Sanchez, M. G., Sanchez, A. M., Ruiz-Llorente, L. & Diaz-Laviada, I. Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Lett 555, 561-566 (2003).
357. Lavon, I. et al. A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation. Mol Pharmacol 64, 1334-1341 (2003).
358. Grotenhermen, F. & Muller-Vahl, K. IACM 2nd Conference on Cannabinoids in Medicine. Expert Opin Pharmacother 4, 2367-2371 (2003).
359. Keren, O. & Sarne, Y. Multiple mechanisms of CB1 cannabinoid receptors regulation. Brain Res 980, 197-205 (2003).
360. Kozak, K. R., Prusakiewicz, J. J., Rowlinson, S. W., Prudhomme, D. R. & Marnett, L. J. Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid anandamide. Biochemistry 42, 9041-9049 (2003).
361. Gilgun-Sherki, Y., Melamed, E., Mechoulam, R. & Offen, D. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6- hydroxydopamine-lesioned rats. Pharmacol Toxicol 93, 66-70 (2003).
362. Radbruch, L. & Nauck, F. [A review of side effects and complications with cannabinoid treatment]. Schmerz 17, 274-279 (2003).
363. Glaser, S. T. et al. Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A 100, 4269-4274 (2003).
364. Jonsson, K. O. et al. AM404 and VDM 11 non-specifically inhibit C6 glioma cell proliferation at concentrations used to block the cellular accumulation of the endocannabinoid anandamide. Arch Toxicol 77, 201-207 (2003).
365. Hinz, B., Ramer, R. & Brune, K. Induction of COX-2 expression by the endocannabinoid derivative R(+)-methanandamide. Adv Exp Med Biol 525, 145- 152 (2003).
366. Grotenhermen, F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42, 327-360 (2003).
367. Croxford, J. L. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 17, 179-202 (2003).
368. Reggio, P. H. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors. Curr Pharm Des 9, 1607-1633 (2003).
369. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD. Drugs R D 4, 306-309 (2003).
370. Gallily, R. et al. gamma-Irradiation Enhances Apoptosis Induced by Cannabidiol, a Non-psychotropic Cannabinoid, in Cultured HL-60 Myeloblastic Leukemia Cells. Leuk Lymphoma 44, 1767-1773 (2003).
371. Gomez Del Pulgar, T., De Ceballos, M. L., Guzman, M. & Velasco, G. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 277, 36527- 36533 (2002).
372. Kozak, K. R. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277, 44877-44885 (2002).
373. Hashibe, M., Ford, D. E. & Zhang, Z. F. Marijuana smoking and head and neck cancer. J Clin Pharmacol 42, 103S-107S (2002).
374. Rubovitch, V., Gafni, M. & Sarne, Y. The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 101, 93-102 (2002).
375. Hinnebusch, B. F., Meng, S., Wu, J. T., Archer, S. Y. & Hodin, R. A. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J Nutr 132, 1012-1017 (2002).
376. Inui, A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52, 72-91 (2002).
377. Carter, G. T. & Weydt, P. Cannabis: old medicine with new promise for neurological disorders. Curr Opin Investig Drugs 3, 437-440 (2002).
378. Germain, N., Boichot, E., Advenier, C., Berdyshev, E. V. & Lagente, V. Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF- alpha production by human mononuclear cells. Int Immunopharmacol 2, 537-543 (2002).
379. Smith, P. F. Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. Curr Opin Investig Drugs 3, 859-864 (2002).
380. Bifulco, M. & Di Marzo, V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 8, 547-550 (2002).
381. Sarafian, T. A., Kouyoumjian, S., Tashkin, D. & Roth, M. D. Synergistic cytotoxicity of Delta(9)-tetrahydrocannabinol and butylated hydroxyanisole. Toxicol Lett 133, 171-179 (2002).
382. McKallip, R. J. et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100, 627-634 (2002).
383. Parolaro, D., Massi, P., Rubino, T. & Monti, E. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids 66, 319-332 (2002).
384. Fernandez-Ruiz, J., Lastres-Becker, I., Cabranes, A., Gonzalez, S. & Ramos, J. A. Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot Essent Fatty Acids 66, 257-267 (2002).
385. Kozak, K. R. & Marnett, L. J. Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66, 211-220 (2002).
386. Pertwee, R. G. & Ross, R. A. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66, 101-121 (2002).
387. Esposito, G. et al. The endocannabinoid system protects rat glioma cells against HIV-1 Tat protein-induced cytotoxicity. Mechanism and regulation. J Biol Chem 277, 50348-50354 (2002).
388. Galve-Roperh, I., Rueda, D., Gomez del Pulgar, T., Velasco, G. & Guzman, M. Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol Pharmacol 62, 1385-1392 (2002).
389. Maccarrone, M., Pauselli, R., Di Rienzo, M. & Finazzi-Agro, A. Binding, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. Biochem J 366, 137-144 (2002).
390. van der Stelt, M. et al. Oxygenated metabolites of anandamide and 2- arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. J Med Chem 45, 3709-3720 (2002).
391. Zhou, D. & Song, Z. H. CB1 cannabinoid receptor-mediated tyrosine phosphorylation of focal adhesion kinase-related non-kinase. FEBS Lett 525, 164- 168 (2002).
392. Ek, S., Hogerkorp, C. M., Dictor, M., Ehinger, M. & Borrebaeck, C. A. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res 62, 4398-4405 (2002).
393. De Petrocellis, L. et al. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol 16, 297-302 (2002).
394. Ishii, I. & Chun, J. Anandamide-induced neuroblastoma cell rounding via the CB1 cannabinoid receptors. Neuroreport 13, 593-596 (2002).
395. Jorda, M. A. et al. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood 99, 2786-2793 (2002).
396. Gomez del Pulgar, T., Velasco, G., Sanchez, C., Haro, A. & Guzman, M. De novo- synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J 363, 183-188 (2002).
397. Zurcher, G. [Anorectic syndrome]. Z Gastroenterol 40 Suppl 1, S71-S5 (2002). 398. Melck, D. et al. Cannabimimetic eicosanoids in cancer and inflammation: an
update. Adv Exp Med Biol 507, 381-386 (2002). 399. Kalant, H. Medicinal use of cannabis: history and current status. Pain Res Manag 6,
80-91 (2001). 400. Walker, J. M., Strangman, N. M. & Huang, S. M. Cannabinoids and pain. Pain Res
Manag 6, 74-79 (2001).